Parma, 30 January 2023 Chiesi, the international research-focused biopharmaceutical Group, is pleased to announce Giuseppe Accogli as new Group CEO. He will join Chiesi effective April 3rd 2023, following an extensive and accurate international search.
Giuseppe Accogli is a successful Executive Leader with 25 years of international experience in the med-tech sector of reputed and complex companies such as Baxter and Medtronic.
He brings a strong background across multiple disciplines (such as Sales, Marketing, R&D, M&A, strategy and product innovation), with a focus on the US and EMEA markets.
The combination of his experience, values, and drive makes him an ideal fit for Chiesi Group.
“I am honored to lead Chiesi into its new stages of growth and I thank the Board of Directors for their trust and the opportunity they are giving me to be part of such an exciting journey” Giuseppe Accogli says. “At its core, Chiesi is a Group of innovative and highly committed professionals who care for the health and wellbeing of people around the world leaving a positive impact in the environment and the communities in which the company operates. As CEO, I strive to enable our leaders, people and partners to achieve even greater success in fulfilling this commitment to be a sustainable force for good in the biopharmaceutical industry.”
“We are thrilled to have Giuseppe in the CEO role,” Alberto Chiesi, President of Chiesi Group, says. “He is a proven leader with the vision and the strength to expand on the success Chiesi has built over the past 85 years and take us into our next phase of growth and innovation.”
Marco Vecchia, who has been acting Chief Executive Officer as well as Head of Global Strategy & Corporate Development and Head of Legal and Corporate Affairs for the last months will continue as Head of Legal and Corporate Affairs.
The Board of Directors and the Management Team will ensure leadership continuity in this transitional phase while Giuseppe completes his on boarding.
About Chiesi Group
Chiesi is an international, research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.
By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi’s commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making. Since 2019 Chiesi is certified B Corp, meaning that its sustainability efforts are measured and assessed by the most ambitious global standards. The company aims at becoming net-zero by 2035.
With over 85 years of experience, Chiesi is headquartered in Parma (Italy), operates in 30 countries, and counts more than 6,000 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.
Contact for media: mediarelations@chiesi.com
